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Introduction
Gastric cancer is the second commonest cause of can-
cer-associated death in the world [1]. Although surgical
treatment in early stages may offer cure of the disease,
many patients present with micrometastases. In such sit-
uation, chemotherapy might be warranted [2]. Molecu-
lar markers of solid tumors, if accessible, can not only
be useful in classifying the cancer, but they can also sug-
gest dissemination of the disease [3]. 
Neo-angiogenesis is of crucial importance for gas-
tric cancer growth and nutrition, with vascular
endothelial growth factor (VEGF) being the most
important growth factor involved in the process [4].
VEGF plays an important role in progression, invasion
and spread of several gastrointestinal cancers, includ-
ing gastric cancer. The tissue expression of VEGF can
be associated with lymph node metastases and indicat-
ed poor prognosis [5]. Because of positive correlation
between blood concentration of VEGF and the stage of
gastric cancer [6], there have been trials to inhibit
angiogenesis in gastric cancer [7].
VEGF-A, which is the most important form of
VEGF, acts via its two receptors, VEGFR1 (or Flt-1)
and VEGFR2 (or KDR) [8]. They are expressed almost
exclusively in the endothelium of vessels lining or
penetrating solid tumors  [9]. VEGFR2 has critical
functions in physiological and pathological angiogen-
esis [8]. The expression of VEGFR2 in intestinal-type
gastric cancer was found to correlate with the vessel
count and the stage of disease [10]. There is evidence
that VEGFR2 plays a key role in regulation of prolif-
eration of gastric cancer cells [11]. A soluble form of
VEGFR2 was also described, with potential to inhibit
angiogenesis [12]. So far no data are available on sol-
uble VEGFR2 in gastric cancer.
One of the recently described substances important
for angiogenesis is endoglin [5]. Endoglin, also known
as CD105, is a trans-membrane co-receptor for TGF-
β1 and TGF- β3. It modulates the cell response to
those mediators. Endoglin is induced by hypoxia. It is
present mainly in new vessels. Therefore it is very use-
ful for assessment of neo-angiogenesis of malignant
neoplasms [13]. Endoglin assessed in gastric cancer
tissues using immunohistochemistry was shown to
correlate with newly formed blood vessels [14]. 
Endoglin is expressed not only on cell surface, since
its soluble form can be detected also in blood [15]. Until
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now, there are no sufficient data on endoglin in blood
of patients with gastric cancer .
The aim of our study was to assess the usefulness
of soluble angiogenesis markers such as endoglin and
VEGFR2 in gastric cancer patients and to compare
these results with those of VEGF levels. As a second-
ary objective, we compared the concentrations of all
three soluble markers in plasma and serum. We also
assessed the levels of all molecules in few patients
with non-cancerous gastric tumors: lymphomas and
gastro-intestinal stromal tumors.
Materials and methods
Patients. The studies were performed on plasma and serum sam-
ples from 30 patients with gastric tumors treated in the II Depart-
ment of General and Gastroenterological Surgery, Medical Univer-
sity of Bialystok. This group comprised 26 patients with gastric
cancer (17 intestinal-type – Lauren I and 9 diffuse-type – Lauren
II), lymphoma (B cell lymphoma) in 2 patients and gastro-intestin-
al stromal tumor (GIST) in 2. The group of patients with gastric
tumors was characterized in Table 1.
The control group consisted of 24 apparently healthy subjects.
It comprised 13 men and 11 women, aged 32 to 78 (mean 64,9).
These were apparently healthy subjects. Patients and volunteers
with clinical or laboratory signs of infection were excluded from
the study. The study was approved by the local ethical committee.
sPlasma and Serum samples. In all patients, samples were col-
lected before surgery and at post-operative day 10. After overnight
fasting, 4.5 ml venous blood was poured into a tube. After clot for-
mation, specimens were centrifuged at 1000 rpm for 15 minutes in
4°C. The supernatant – serum was transferred to Eppendorf's tube
and frozen in -70°C until determination. For plasma collection,
tubes with 0.5 ml EDTA were used. Immediately after sampling,
specimens were centrifuged at 1000 rpm for 15 minutes in 4°C.
The supernatant – platelet poor plasma was transferred to Eppen-
dorf's tube and frozen at -70°C until analysis. 
Plasma and serum samples were used for ELISA determinations.
VEGF-A, sVEGFR2 and endoglin were assessed using commer-
cially available ELISA kits purchased from Research Diagnostics
Inc., USA.
Statistical analysis. Statistical analysis. Shapiro-Wilk test was
used for assessing normality. Kruskal-Wallis ANOVA, Mann-
Whitney, Wilcoxon and Spearman's tests were used accordingly.
Results are given as median; full range (minimum, maximum). 
A value of p<0.05 was regarded as significant. As there were only
two patients with both lymphoma or GIST, no analysis was per-
formed for those groups.
Results
In our study, we treated values of VEGF-A <4 pg/ml as
below detection range. This was the case in 9 out of 24
control subjects. We found a significant increase in
VEGF-A concentration in plasma of the patients with
both intestinal-type and diffuse-type gastric cancer
(type I and II according to Lauren) (p<0.05 for both)
(Fig. 1), as compared to the control group. The level of
VEGF did not differ significantly between the two
subgroups of gastric cancer patients. In the two
patients with gastric lymphoma VEGF level was over
6-fold greater than in other groups of patients.
As can be seen in Fig. 2, VEGFR2 showed a ten-
dency towards similar changes as VEGF-A, however
without significant differences. We found a positive
correlation between preoperative VEGF-A and
VEGFR2 values in gastric cancer patients (Spearman's
R=0.42, with p<0.05). The highest levels (but not
exceeding 2-fold increase) were observed in the two
lymphoma patients. In the two patients with GIST the
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Table 1. Clinical and pathological characteristics of the gastric
tumor patients
plasma concentrations of VEGFR2 were lower than
those of the control group or gastric cancer patients.
Endoglin concentrations in plasma of the patients
with gastric tumors and those in the control group did
not differ significantly (Fig. 3). 
When comparing plasma and serum levels of the
markers assessed in gastric cancer patients (Fig. 4), we
found much greater values of VEGF in serum than in
plasma, with a 3-fold difference for Lauren II type
(p<0.01) and 10-fold for Lauren I type (p<0.001).
There was a high positive correlation between plasma
and serum VEGF (Spearman's R=0.76 with p<0.05,
data not shown). As far as VEGFR2 is concerned, the
values did not change significantly whether assessed
in plasma or in serum (Fig. 5). The median values of
endoglin obtained in plasma samples tended to be
about 20% lower than those found in serum, but the
difference was not significant  (Fig. 6). There was a
high positive correlation between the values obtained
for plasma and serum samples (Spearman's R=0.82
with p<0.05 – data not shown).
Operation resulted in a marked increase in VEGF in
the plasma of both gastric cancer groups as compared
to the preoperative values (p<0,05 for Lauren I and
Lauren II.) (Fig. 7). A similar tendency was observed
for patients with Lymphoma and GIST.
We did not observe any significant changes in
VEGFR2 concentrations before and 10 days after sur-
gical treatment (Fig. 8). However, when comparing
postoperative VEGFR2 in metastasis-positive and
metastasis-negative patients, we found markedly
greater values in the latter subgroup (p<0.001 – data
not shown).
In contrast to VEGF, postoperative endoglin con-
centrations in serum of gastric cancer patients dropped
significantly (p<0,05) for Lauren I type (Fig. 9). No
other differences were observed.
We did not find any significant correlations
between VEGF, VEGFR2 or endoglin in plasma or
serum and any clinical or pathological parameters of
gastric cancer stage in our patients.
Discussion
Angiogenesis is a key process leading to gastric cancer
growth, invasion and dissemination. Among numerous
substances involved in new vessel formation, VEGF is
one of the best characterized [16]. VEGF expression
enhancement has been previously demonstrated in
gastric cancer patients when compared to normal con-
trols. An association of VEGF serum concentrations
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Fig. 1. Preoperative concentration of VEGF-A in plasma of normal
controls (control), and patients with different gastric tumors: gas-
tric cancer of type I according to Lauren (Lauren I), gastric cancer
of type II according to Lauren (Lauren II), lymphoma and gas-
trointestinal stromal tumor (GIST). Results are given as median,
full range. * – significant difference from control group at p<0.05.
For Lymphoma and GIST groups no statistical analysis was per-
formed (N=2 in both groups).
Fig. 2. Preoperative concentration of VEGF-R2 in plasma of nor-
mal controls (control), and patients with different gastric tumors:
gastric cancer of type I according to Lauren (Lauren I), gastric can-
cer of type II according to Lauren (Lauren II), lymphoma and gas-
trointestinal stromal tumor (GIST). Results are given as median,
full range. No significant differences were found. For Lymphoma
and GIST groups no statistical calculation was performed (N=2 in
both groups).
Fig. 3. Preoperative concentration of endoglin in plasma of nor-
mal controls (control), and patients with different gastric tumors:
gastric cancer of type I according to Lauren (Lauren I), gastric can-
cer of type II according to Lauren (Lauren II), lymphoma and gas-
trointestinal stromal tumor (GIST). Results are given as median,
full range. No significant differences were found. For Lymphoma
and GIST groups no statistical calculation was performed.
with tumor grade and size were also reported [17]. It
was also shown that VEGF may play a role in peri-
toneal recurrence of gastric cancer [18]. 
Our results show an increase in plasma VEGF-A in
both intestinal-type and diffuse-type gastric cancer
patients when compared with healthy subjects (Fig. 1).
This is in accordance with previous publications
reporting that VEGF-A levels in both plasma and
serum were greater in gastric cancer patients than in
the control group [19]. 
After the operation, at postoperative day 10, we
observed a significant increase in VEGF levels in both
groups of patients with gastric cancer (Fig. 4). Ding et
al. [19] assessed VEGF-A levels 3 weeks after the
operation and found a decrease in VEGF-A concentra-
tions. Different times of blood sampling may at least
explain partly the difference with our study. There is
evidence that in oxidative stress results in substantial
increases in VEGF-A production [20]. This might
explain the rise in VEGF-A on postoperative day 10. It
has also been demonstrated that level of serum VEGF
after the operation depends on radicality of resection
[17]. It falls in patients after radical gastrectomy and
rises after palliative operation. Unfortunately in our
study, most patients were operated at an advanced
stage of the disease and the majority of operations
were palliative.
When comparing the values of soluble angiogenesis
markers studied in plasma and serum of patients with
gastric cancer, we found significantly greater values of
VEGF-A in serum than in plasma (Fig. 4). Our results
confirm findings by Ding et al. [19]. We observed a high
positive correlation between plasma and serum values
when paired results were compared. We suggest that
especially VEGF-A in gastric cancer patients should be
assessed in serum rather than in plasma. 
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Fig. 4. Preoperative concentration of VEGF-A in plasma and in
serum of the patients with gastric cancer of type I according to
Lauren (Lauren I), and of type II according to Lauren (Lauren II).
Results are given as median, full range. Significant differences are
marked with **- p<0.01, ***-p<0.001.
Fig. 5. Preoperative concentration of sVEGF-R2 in plasma and in
serum of the patients with gastric cancer of type I according to
Lauren (Lauren I), and of type II according to Lauren (Lauren II).
Results are given as median, full range. Significant differences are
marked with *- p<0.05.
Fig. 6. Preoperative concentration of endoglin in plasma and in
serum of the patients with gastric cancer of type I according to
Lauren (Lauren I), and of type II according to Lauren (Lauren II).
Results are given as median, full range. No significant differences
were found. 
Fig. 7. Influence of operation on the concentration of VEGF-A in
plasma of patients with different gastric tumors: gastric cancer of
type I according to Lauren (Lauren I), gastric cancer of type II
according to Lauren (Lauren II), lymphoma and gastrointestinal stro-
mal tumor (GIST). Results are given as median, full range. Signifi-
cant differences are marked with *- p<0.05. For Lymphoma and
GIST groups no statistical calculation was performed (N=2 in both
groups).
We also observed, which has not yet been demon-
strated before, an increase in VEGF-A in the patients
with other stomach tumors: GIST and lymphoma (Fig.
1). However, as there were only two patients with
either type of non-cancerous gastric neoplasms includ-
ed in our study, these findings need confirmation. It
has been reported that VEGF is strongly expressed in
diffuse large B cell nodal lymphomas [21]. The level
of circulating VEGF in blood of patients with
leukaemia or non-Hodgkin's lymphoma was described
as a predictor of poor prognosis [22]. VEGF has even
been suggested as a potential target for antiangio-
genetic treatment of aggressive lymphomas [21].
VEGFR2 is one of two types of tissue receptors for
VEGF-A [8]. A soluble form of VEGFR2, which cir-
culates in blood, can bind to VEGF-A and so act as an
inhibitor of angiogenesis [12,23]. Several studies have
confirmed that inhibition of VEGFR2 leads to growth
reduction of human neoplasms [24,25]. Until now, no
data on soluble VEGFR2 in gastric cancer have been
available. We did not demonstrate any significant
change in circulating VEGFR2 in gastric cancer
patients, when compared to healthy subjects (Fig. 2).
However, we found a marked difference between
VEGFR2 in plasma of metastases-negative and -posi-
tive gastric cancer, as assessed postoperatively
(p<0.001). Patients with distant metastases had lower
levels of VEGFR2 as assessed on day 10 postopera-
tively. We speculate that after tumor resection, the only
focus of cancer left corresponds to metastases. As we
show in the present study, VEGF-A level rised after the
operation. As VEGF has been reported to play an
important role in aggressive malignancies, its increase
might be greater in patients with distant metastases.
Also in our patients, postoperative VEGF-A level in
plasma tended to be greater in metastasis-positive than
in metastasis-negative patients (median 130 versus
100 ng/ml), though the difference was not significant.
VEGFR2 might be bound to greater amounts of circu-
lating VEGF-A and so – decrease in the circulation.
The importance of our finding for gastric cancer
patients remains to be established.
Comparative analysis of VEGFR2 concentrations
in plasma and serum showed greater values in serum in
patients with intestinal-type gastric cancer (Lauren I)
(Fig. 5). This was not demonstrated for diffuse-type
cancer group.
Endoglin, a receptor for transforming growth factor
β1 and  β3 is expressed predominantly on newly
formed microvessels. It is crucial for angiogenesis by
modulating endothelial-mesenchymal signalling and
thus enhancing proliferation [26]. Endoglin is also
claimed to be involved in such phenomena as cell
adhesion and migration [27]. Soluble endoglin has
been reported to rise in breast cancer patients who
developed metastases, as compared to both normal
controls and cancer patients without distant spread
[28]. Elevated serum endoglin was associated with dis-
tant metastases not only in breast but also colorectal
and other solid tumors [15]. Until now there were no
reports on endoglin levels in serum in  patients with
gastric cancer. 
Our results did not demonstrate any significant dif-
ferences in endoglin concentrations in plasma of
patients with gastric cancer (Fig. 3). We observed
however greater values of endoglin in the patients with
rare gastric tumors: lymphoma and GIST. As men-
tioned above, this finding needs further confirmation
in larger groups of patients. Interestingly, endoglin
concentrations dropped postoperatively in plasma of
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Fig. 8. Influence of operation on the concentrations of sVEGF-R2
in serum of patients with different gastric tumors: gastric cancer of
type I according to Lauren (Lauren I), gastric cancer of type II
according to Lauren (Lauren II), lymphoma and gastrointestinal
stromal tumor (GIST). Results are given as median, full range. No
significant differences were found. For Lymphoma and GIST
groups no statistical analysis was performed (N=2 in both groups)
Fig. 9. Influence of operation on the concentration of endoglin in
serum of patients with different gastric tumors: gastric cancer of
type I according to Lauren (Lauren I), gastric cancer of type II
according to Lauren (Lauren II), lymphoma and gastrointestinal
stromal tumor (GIST). Results are given as median, full range.
Significant difference is marked with *- p<0.05. For Lymphoma
and GIST groups no statistical analysis was performed (N=2 in
both groups).
patients with intestinal type (Lauren I) gastric cancer
and had a similar tendency in diffuse-type cancer (Fig.
9). The possible explanation might be the removal of
the tumor.
The assessment of endoglin in plasma and serum
showed a tendency for greater serum levels (Fig. 6),
though the difference was not significant. 
We failed to demonstrate a correlation between
endoglin and the stage of gastric cancer. This might be
attributed to the difference between tissue expression
of this angiogenic compound and the level of its circu-
lating form. 
In summary, we showed increases in circulating
VEGF-A in patients with both types of gastric cancer
(Lauren I and II). The levels of VEGFR2 did not change
significantly in patients with gastric cancer as compared
to healthy subjects. Interestingly, after the operation
greater levels of VEGFR2 were observed in patients
without metastases. Both VEGF and VEGFR2 circulat-
ing levels were greater in patients with lymphoma, when
compared to both gastric cancer patients and the control
group. However, because of small number of patients,
this requires further studies. Presented data suggests that
endoglin does not seem to be a valuable tool in the
assessment of gastric cancer invasion and spread. 
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